Vai al contenuto principale della pagina

Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode]



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Titolo: Defining optimal immunotherapies for type 1 diabetes [[electronic resource] /] / [editors: Gregory Bock and Jamie Goode] Visualizza cluster
Pubblicazione: London, : Novartis Foundation, 2008
Descrizione fisica: 1 online resource (224 p.)
Disciplina: 616.46206
Soggetto topico: Diabetes - Immunotherapy
Diabetes - Treatment
Soggetto genere / forma: Electronic books.
Note generali: Description based upon print version of record.
Nota di bibliografia: Includes bibliographical references and index.
Nota di contenuto: Defining Optimal Immunotherapies for Type 1 Diabetes; Contents; Participants; Chair's introduction; Pancreatic pathology in type 1 diabetes in human; The b cell population in type 1 diabetes; Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulation; Resuscitating adaptive Tregs with combination therapies?; Cytotoxic T cell mechanisms of b cell destruction in non-obese diabetic mice; Type 1 diabetes: chronic progressive autoimmune disease; Current and past prevention and intervention trials in type 1 diabetes
CD8 and cytotoxic T cells in type 1 diabetesGeneral discussion I; General discussion II; Genetic and therapeutic control of diabetogenic CD8+ T cells; General discussion III; Towards a curative therapy in type 1 diabetes: remission of autoimmunity, maintenance and augmentation of b cell mass; Immune markers of disease and therapeutic intervention in type 1 diabetes; Re-establishing immune tolerance in type 1 diabetes via regulatory T cells; Translating mucosal antigen based prevention of autoimmune diabetes to human; Closing remarks; Contributor index; Subject index
Sommario/riassunto: This book is a comprehensive and up-to-date account of where we stand in immunological strategies for preventing or treating type 1 diabetes (T1D).Brings together contributions from the leaders in the arena of clinical immunotherapy, not limited to the diabetes field exclusively, in order to delineate a road-map that would lead to future clinical trials.The book integrates information from human and animal studies.The book considers T1D within the broader context of autoimmune disease.The format contains several discussions, which address specific questions and provides
Titolo autorizzato: Defining optimal immunotherapies for type 1 diabetes  Visualizza cluster
ISBN: 1-281-84052-1
9786611840525
0-470-69740-7
0-470-69741-5
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910144093303321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui
Serie: Novartis Foundation symposium ; ; v. 292.